Are we the lab rats of pharmaceutical companies?
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Friday
January 27, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
FRIDAY, JANUARY 27, 2023
Are we the lab rats of pharmaceutical companies?

Thoughts

Pritha Tiffany Patwary
25 January, 2021, 11:00 am
Last modified: 25 January, 2021, 11:00 am

Related News

  • Pharma industry needs to prepare for headwinds
  • Pharma companies: A safe haven for investors in this bear market
  • Top drugmakers keep growth trajectory in H1
  • Most pharma companies post higher annual profits
  • Three pharma companies ordered to repay intercompany loans

Are we the lab rats of pharmaceutical companies?

Pharmaceutical companies use various tactics to encourage the overuse of allopathic care

Pritha Tiffany Patwary
25 January, 2021, 11:00 am
Last modified: 25 January, 2021, 11:00 am
Pritha Tiffany Patwary. Illustration: TBS
Pritha Tiffany Patwary. Illustration: TBS

In this digital era, there is no dearth of information and access to that is made easy with the advent of different communication mediums. The world of patients and diseases also can't save themselves from this information overdose. People are now self-diagnosing themselves with their symptoms and asking their doctors for medications accordingly, even though the physicians are trained professionals who can give better advice. Pharmaceutical companies use various tactics to encourage the overuse of allopathic care. For instance, in the case of cholesterol, people can make long-term life adjustments through their diet and exercise, but medications are more frequently prescribed. Not only is disinformation one of the factors behind it but also, pharmaceutical companies incentivise doctors to prescribe certain medicines by giving them several fringe benefits. 

The overuse of allopathic treatment also impacts the environment which is one of its lesser-known effects. A Canadian study found that the drugs we consume which are eventually disposed of can make its way into rivers, streams and tap water as well. Drug disposal or ''dumping'' is yet to be studied more in-depth, but there is evidence that the fish and birds are suffering due to the surplus of estrogen in the water. 

Pharmaceutical companies essentially also invent diseases (known as disease-mongering) in order to keep their profits steady. They have the power to convince people that they need those medications for their so-called conditions. When Merck produced a medication that would prevent hair loss, they advertised balding as a medical condition. 

The pursuit of profits can have detrimental consequences. Thalidomide was marketed as a very safe sleeping pill and used for flu and nervousness, among other conditions. The human cost of maximising profits from thalidomide were 100 babies in Canada who were born without limbs in 1954. The side effects of this drug came out in 1959, yet the damage had already been done by then. 

Initially, a West German company developed thalidomide (sold as GRIPPEX in 1954). Much like antibiotics nowadays, it was widely accessible, affordable and could be purchased without a prescription. So much was its safety emphasised in advertisements that in the United Kingdom (where it was sold as Distavel), it contained a picture of a child titled "This child's life may depend on the safety of Distavel.'' 

Representational image. PHOTO: Reuters
Representational image. PHOTO: Reuters

The drug company had also published an article in the 1961 issue of the American Journal of Obstetrics and Gynecology, under the name of Dr Ray Neilson of Cincinnati even though it had been actually written by a medical research director of the pharmaceutical company. To make matters worse, the evidence used to promote the drug to pregnant women who took the medicine a few months before delivery when the baby already grew limbs. Companies continued to market the drug as safe for use despite evidence arising in 1959 that it was dangerous to consume especially if taken during the earlier months of pregnancy, that is before the limbs had developed. 

Such tragic incidents did not stop with thalidomide. For contraceptives, there was Essure, a metal coil designed to be used as a form of permanent birth control by inserting it into the fallopian tubes. It was suggested by doctors who stated its convenience of taking only a few minutes to insert. However, Essure was launched in the market based on short-term studies. Hundreds of women across the United States, Canada and the United Kingdom suffered from bleeding and excruciating pain which disrupted their daily lives. When they reported these symptoms to their doctors, it was dismissed as problems they made up in their heads. The only solution became the removal of the uterus as it was complicated to remove the coils. In this case, essentially the women who had trusted their doctors and got implanted with Essure became the long-term test subjects. 

Prescriptions usually come in a piece of paper, but its weight is underestimated. The testing of the effectiveness of medication itself is flawed as samples are derived from primarily young males in their 30s. Often, women and old people are not included in these tests. Older people may not absorb medication in the same way that the younger males in the testing do as their metabolism may differ. Essentially, as all the incidents show, pharmaceuticals rely on trial and error after the medications reach their consumers. Once the money is extracted, the damage is already done.

It is safe to say that 2020 has been the year where people united in their worries. One of them is the wait for the vaccine, among other things. As vaccines are released, one can only wonder what side effects may come out of it as we become the long-term test subjects of it. 


The author is a 2nd-year undergraduate student studying Global Health with a focus in Global Health Promotion and Disease Prevention at York University in Toronto.


Disclaimer: The views and opinions expressed in this article are those of the author and do not necessarily reflect the opinions and views of The Business Standard. 

Top News

lab rats / pharmaceutical companies

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Manufacturers feel the pinch as consumers tighten belt
    Manufacturers feel the pinch as consumers tighten belt
  • Sugar turning bitter!
    Sugar turning bitter!
  • Island hopping in Bangladesh?
    Island hopping in Bangladesh?

MOST VIEWED

  • Sketch: TBS
    'Amrit Kaal' of the Indian economy
  • Illustration: TBS
    Australia Day 2023: The past, present and future of Australia-Bangladesh relations
  • Sketch:TBS
    The power of nonverbal behaviour in classroom education
  • Big tech helps big oil spread subtle climate denialism
    Big tech helps big oil spread subtle climate denialism
  • Sketch: TBS
    Time for Bangladesh to develop skilled human resources for the blue economy industry
  • Sketch: TBS
    Class-clown brands are trying to lolz us to death

Related News

  • Pharma industry needs to prepare for headwinds
  • Pharma companies: A safe haven for investors in this bear market
  • Top drugmakers keep growth trajectory in H1
  • Most pharma companies post higher annual profits
  • Three pharma companies ordered to repay intercompany loans

Features

Island hopping in Bangladesh?

Island hopping in Bangladesh?

1h | Panorama
According to the CAB president Ghulam Rahman, one of the most common complaints of consumers is being deceived by sellers when it comes to the weight of goods. Photo: TBS

Has the Directorate improved consumer rights in Bangladesh?

2d | Panorama
A 2022 survey of 1,000 companies by professional services consultancy PwC found that between a sixth and a quarter had used AI in recruitment or employee retention in the past 12 months. Illustration: Bloomberg

AI is coming to your workplace. Is the world ready?

2d | Panorama
Edison Desdemona, the newly launched stellar project of Edison Real Estate, located at Bashundhara Residential Area. Photo: Courtesy

EDISON DESDEMONA: A creation like no other

2d | Habitat

More Videos from TBS

Kajol’s road paintings bring change in Gafargaon

Kajol’s road paintings bring change in Gafargaon

13h | TBS Stories
Carew & Company witnessed a remarkable growth

Carew & Company witnessed a remarkable growth

14h | TBS Stories
PCB recalls cricketers from BPL ahead of PSL

PCB recalls cricketers from BPL ahead of PSL

16h | TBS SPORTS
Why Misha Sawdagar became villain instead of a Hero?

Why Misha Sawdagar became villain instead of a Hero?

15h | TBS Entertainment

Most Read

1
Picture: Collected
Bangladesh

US Embassy condemns recent incidents of visa fraud

2
Four top bankers arrested in DSA case filed by S Alam group 
Bangladesh

Four top bankers arrested in DSA case filed by S Alam group 

3
Illustration: TBS
Banking

16 banks at risk of capital shortfall if top 3 borrowers default

4
Photo: Collected
Splash

Hansal Mehta responds as Twitter user calls him 'shameless' for making Faraaz

5
A frozen Beyond Burger plant-based patty. Photographer: AKIRA for Bloomberg Businessweek
Bloomberg Special

Fake meat was supposed to save the world. It became just another fad

6
Representational Image
Banking

Cash-strapped Islami, Al-Arafah and National turn to Sonali Bank for costly fund

EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]